Market Overview

US Stock Futures Up Ahead Of Jobless Claims Data

Share:
US Stock Futures Up Ahead Of Jobless Claims Data
Related SJM
Twitter May Have Co-CEOs: Good Or Bad News For Shareholders?
Longs Getting Jammed In JM Smucker
What's in Store for Procter & Gamble's (PG) Q4 Earnings? - Analyst Blog (Zacks)
Related ONCY
US Stock Futures Signal Lower Start On Wall Street
Oncolytics Announces Collaborators to Present REOLYSIN Preclinical Data at ICOVT
Oncolytics: An Unheralded Biotech With Promising Phase 2 Results (Seeking Alpha)

Pre-open movers

US stock futures rose in early pre-market trade, ahead of jobless claims data. Data on weekly jobless claims and the producer price index will be released at 8:30 a.m. ET. The Markit PMI manufacturing index (flash) for November will be released at 8:58 a.m. ET, while the general business conditions index will be released at 10:00 a.m. ET. Futures for the Dow Jones Industrial Average surged 38 points to 15,916.00, while the Standard & Poor's 500 index futures rose 3.80 points to 1,783.50. Futures for the Nasdaq 100 index gained 10 points to 3,376.50.

A Peek Into Global Markets

European markets were mostly lower today, with the Spanish Ibex Index falling 0.02%, London's FTSE 100 index gaining 0.06% and STOXX Europe 600 Index dropping 0.19%. German DAX 30 index fell 0.24% and French CAC 40 Index tumbled 0.53%. German manufacturing PMI surged to 52.5 in November, while the manufacturing PMI for France dropped to 47.8 in the month.

Asian markets ended mostly lower today. Japan's Nikkei Stock Average surged 1.92%, China's Shanghai Composite declined 0.04%, Hong Kong's Hang Seng Index fell 0.51% and India's BSE Sensex dropped 1.97%.

Broker Recommendation

Analysts at JP Morgan downgraded J.M. Smucker Company (The) (NYSE: SJM) from “overweight” to “neutral.” The target price for Smucker has been lowered from $123 to $118.

Smucker's shares closed at $101.49 yesterday.

Breaking news

  • Oncolytics Biotech (NASDAQ: ONCY) today announced positive top-line data for the endpoints in its double blinded, randomized clinical study examining REOLYSIN in combination with carboplatin and paclitaxel in patients with second-line platinum-refractory, taxane-naïve head and neck cancers (REO 018). To read the full news, click here.
  • ChipMOS Technologies (NASDAQ: IMOS) today announced that its Board of Directors has approved the repurchase of 12.2% ownership position in ChipMOS from the Company's subsidiary, ThaiLin Semiconductor Corporation. To read the full news, click here.
  • A consortium led by KKR Asset Management, a leading sub-investment grade manager that is wholly owned by KKR (NYSE: KKR) today announced it has entered into an agreement to acquire Winoa Group from LBO France. To read the full news, click here.
  • Sequans Communications (NYSE: SQNS) today announced the pricing of an underwritten public offering of American Depositary Shares (ADSs), representing 12,500,000 ordinary shares, at a price of $1.80 per ADS. To read the full news, click here.

Posted-In: JP Morgan US Stock FuturesNews Eurozone Futures Global Pre-Market Outlook Markets

 

Related Articles (IMOS + KKR)

Get Benzinga's Newsletters